- Report
- September 2024
- 150 Pages
Global
From €4467EUR$4,850USD£3,775GBP
- Report
- April 2025
- 550 Pages
Global
€2717EUR$2,950USD£2,296GBP
- Report
- October 2025
- 90 Pages
Bahrain
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 88 Pages
Saudi Arabia
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 82 Pages
Qatar
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 96 Pages
Saudi Arabia
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 90 Pages
Kuwait
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 90 Pages
Kuwait
From €4145EUR$4,500USD£3,503GBP
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 100 Pages
Middle East
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 95 Pages
Turkey
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 87 Pages
South Korea
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 94 Pages
India
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 98 Pages
South Korea
From €4145EUR$4,500USD£3,503GBP
- Report
- October 2025
- 90 Pages
Saudi Arabia
From €4145EUR$4,500USD£3,503GBP
- Report
- September 2025
- 91 Pages
Poland
From €4145EUR$4,500USD£3,503GBP
- Report
- September 2025
- 95 Pages
United States
From €4145EUR$4,500USD£3,503GBP
- Report
- September 2025
- 95 Pages
Germany
From €4145EUR$4,500USD£3,503GBP
- Report
- September 2025
- 88 Pages
United Kingdom
From €4145EUR$4,500USD£3,503GBP
- Report
- September 2025
- 81 Pages
United Kingdom
From €4145EUR$4,500USD£3,503GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more